奥氮平与安慰剂治疗成人门诊神经性厌食症的随机临床试验
这项在北美五中心开展的随机双盲安慰剂对照试验纳入152例成人门诊神经性厌食症患者(96%为女性,平均BMI 16.7),比较奥氮平与安慰剂16周的效果。结果显示奥氮平组BMI随时间增加幅度显著大于安慰剂组,但YBOCS强迫思维评分变化组间无显著差异,代谢相关血液检查异常频率亦无显著差异。
要点
- 奥氮平对成人门诊神经性厌食症患者的体重增加有适度疗效。
- 奥氮平对强迫思维等心理症状未见显著获益。
- 两组代谢相关血液检查异常频率无显著差异。
核心结论
- 奥氮平相比安慰剂对成人门诊神经性厌食症患者的体重有适度治疗效应,但对心理症状无显著获益。
研究设计与样本
- 随机双盲安慰剂对照试验,在北美五个中心开展,纳入152例成人门诊神经性厌食症患者(96%为女性,平均BMI 16.7),按1:1随机分配至奥氮平或安慰剂,每周随访共16周。
主要发现
- 观察到显著的治療×时间交互作用,奥氮平组BMI随时间增加幅度大于安慰剂组(0.259 [SD=0.051] 对比 0.095 [SD=0.053] 每月)。
- YBOCS强迫思维子量表评分随时间变化组间无显著差异(-0.325 对比 -0.017 分每月)。
- 评估潜在代谢紊乱的血液检查异常频率组间无显著差异。
关键数值与推荐
- 主要结局为体重变化率和YBOCS评估的强迫性变化率。
- 奥氮平组BMI每月增加0.259(SD=0.051),安慰剂组每月增加0.095(SD=0.053)。
- YBOCS强迫思维子量表评分奥氮平组每月变化-0.325分,安慰剂组每月变化-0.017分,组间无显著差异。
临床怎么用
- 对于成人门诊神经性厌食症患者,奥氮平可能有助于适度增加体重,但不应期望其显著改善强迫思维等心理症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated the benefits of olanzapine compared with placebo for adult outpatients with anorexia nervosa. METHODS: This randomized double-blind placebo-controlled trial of adult outpatients with anorexia nervosa (N=152, 96% of whom were women; the sample's mean body mass index [BMI] was 16.7) was conducted at five sites in North America. Participants were randomly assigned in a 1:1 ratio to receive olanzapine or placebo and were seen weekly for 16 weeks. The primary outcome measures were rate of change in body weight and rate of change in obsessionality, assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS). RESULTS: Seventy-five participants were assigned to receive olanzapine and 77 to receive placebo. A statistically significant treatment-by-time interaction was observed, indicating that the increase in BMI over time was greater in the olanzapine group (0.259 [SD=0.051] compared with 0.095 [SD=0.053] per month). There was no significant difference between treatment groups in change in the YBOCS obsessions subscale score over time (-0.325 compared with -0.017 points per month) and there were no significant differences between groups in the frequency of abnormalities on blood tests assessing potential metabolic disturbances. CONCLUSIONS: This study documented a modest therapeutic effect of olanzapine compared with placebo on weight in adult outpatients with anorexia nervosa, but no significant benefit for psychological symptoms. Nevertheless, the finding on weight is notable, as achieving change in weight is notoriously challenging in this disorder.
引用
- Attia E, Steinglass JE, Walsh BT, et al. Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial. Am J Psychiatry. 2019. PMID: 30654643. doi:10.1176/appi.ajp.2018.18101125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。